Clinical Trial Update: Patent Blue SLN in Early Ovarian Cancer Prospective Study (FIGO I-II) Evaluating Patent Blue SLN Mapping. Injection Into IP/UO Ligaments in Situ. Goals: Assess Feasibility and Accuracy vs Standard Lymphadenectomy to Minimize Surgical Morbidity

View source ↗

Summary

A prospective study in early-stage ovarian cancer is evaluating the feasibility and accuracy of Patent Blue SLN mapping versus standard lymphadenectomy to reduc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Patent Blue SLN (Patent blue dye for sentinel lymph node mapping)

Snippet

Sponsor: Faculty of Medicine of Tunis | Conditions: Sentinel Lymph Node Biopsy (SLNB), Early Stage Ovarian Tumors | Status: RECRUITING